EAG expands biopharma analysis capabilities in 'major investment'

By Melissa Fassbender contact

- Last updated on GMT

The demand for high-end biopharmaceutical analysis is being driven by biosimilars. (Image: iStock/Bogdanhoda)
The demand for high-end biopharmaceutical analysis is being driven by biosimilars. (Image: iStock/Bogdanhoda)

Related tags: Pharmacology, Biotechnology, Investment

EAG has further invested in ABC Laboratories' capacity and analytical capabilities in order to help meet demand for high-end biopharmaceutical analysis. 

The company is calling it a “major investment​,” which is part of a previous multimillion-dollar capital investment in instrumentation. The announcement comes on the heels of EAG’s purchase of Analytical Bio-Chemistry Laboratories (ABC Laboratories), a Contract Research Organization (CRO) providing product development and analytical testing services for small and large molecule therapies.

"The pharmaceutical industry has a critical need for high-quality contract laboratory partners who can perform the complex analyses required to fully characterize a biopharmaceutical​," said EAG's CEO, Siddhartha Kadia, Ph.D. "Since launching its biopharmaceutical offering in 2008, ABC had built a great reputation for its scientific excellence, but the company needed additional capital to strengthen its analytical toolbox​."

According to the company, the FDA’s recent approval of the second biosimilar and the larger number of biotech drugs losing patent protection in the next couple years will drive up demand for these types of services.

"Biotech drug development requires different analytical techniques than traditional 'small molecule' pharmaceuticals, and interpreting study results requires deep insight into the mechanisms of biopharmaceutical behavior​," said Prasad Raje, Ph.D., Senior Vice President of EAG's Life Sciences division.

"Our biopharmaceutical scientists have built a reputation for solving complex analytical issues for our clients​," he added. "Having more advanced analytical equipment will enable them to get there faster, and simultaneously support a greater number of programs​."

Related news

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars